Skip to main content

Sources last read

The research desk

Research you can inspect.

Explore research on drug safety, clinical trials, access and cost. Read the findings, check their limits and download the underlying data.

Inside the research

Reports
11
Datasets
13
Published data
10,432 rows
Source databases
11

Sources last retrieved 2026-09-27. Counts reflect the published datasets.

Featured analysis

Start with the findings

Explore the reports

Research by question

Each report includes its sources, data downloads and citation files.

Safety and use

Safety and use

EGRIFTA 2 mg trial-formulation side-effect rates

What incidence did the EGRIFTA 2 mg, 1 mg/vial trial-formulation table report against placebo?

Side-effect percentages from the EGRIFTA 2 mg (1 mg/vial trial-formulation) table, with the named treatment and comparison arms, both arm sizes, and the fetched label coordinates behind every row.

Rows
20
Read
2026-09-06
Edition
2026.09
Version
2796588441d8
Read the report and inspect the data →

Clinical development

Clinical development

The registered peptide and GLP-1 trial pipeline

Which compounds have registered human trials, and how far have they reached?

For each compound in this monitored trial census, this table counts registered studies and the ones still recruiting. It also shows the highest phase and next main-measurement date. Compounds with no registered study are rows too.

Rows
51
Read
2026-09-27
Edition
2026.09
Version
4a02f8c12e91

A year-by-year count of active, identity-checked registered studies whose sponsor-filed primary-completion date had not passed when the registry was read. Multi-compound studies count once in the study total and once per compound in the association total.

Rows
8
Read
2026-09-27
Edition
2026.09
Version
99b7da09ef52
Read the report and inspect the data →

Access and regulation

Cost and supply

Cost and supply

Federal listings and recalls across the peptide supply chain

What appears in federal drug listings and recall records?

Every listing FDA’s National Drug Code directory holds for these compounds. Each row shows the labeler, marketing category and FDA’s flag for a finished medicine or raw ingredient.

Rows
577
Read
2026-08-17
Edition
2026.08
Version
378fefb14c5f

Every recall record FDA’s enforcement database holds for these compounds. Each row shows the hazard class, process status, recalling firm and FDA’s stated reason.

Rows
308
Read
2026-09-21
Edition
2026.09
Version
5269b522fd7c
Read the report and inspect the data →

Cost and supply

FDA shortage status for GLP-1 drugs

What does FDA currently list as in shortage?

Whether FDA’s drug shortage database lists semaglutide or tirzepatide as in shortage on the date read. Current, closed and discontinued records are counted separately. A drug with no record is a row too.

Rows
2
Read
2026-08-14
Edition
2026.08
Version
c8b4cf25d815
Read the report and inspect the data →

Reuse the work

Use the data in your work

The analysis tables are published under CC BY 4.0. CSV and JSON preserve the rows; BibTeX and RIS preserve the title, edition, version, retrieval date and canonical URL. A source manifest records provenance, limits, rights and exact file hashes. Source rights and our arrangement license are stated separately on every report.

Read the method